Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia
Omar Perbellini, Erika Falisi, Ilaria Giaretta, Elisa Boscaro, Elisabetta Novella, Monica Facco, Stefania Fortuna, Silvia Finotto, Eliana Amati, Francesco Maniscalco, Anna Montaldi, Alberta Alghisi, Fiorenza Aprili, Laura Bonaldi, Rossella Paolini, Maria Teresa Scupoli, Livio Trentin, Achille Ambrosetti, Gianpietro Semenzato, Giovanni PizzoloFrancesco Rodeghiero, Carlo Visco
Istituto Oncologico Veneto
Most patients affected by chronic lymphocytic leukemia are diagnosed by flow cytometry. Several immunophenotypic markers have been identified as significant and independent prognostic variables, especially from retrospective cohorts. However, while attractive because their detection is inexpensive and feasible in most laboratories, only few have been validated by independent series. The expression of leukocyte-associated immunoglobulin-like receptor-1 (also known as LAIR1, LAIR-1 or CD305), an inhibitor of B-cell receptor-mediated signaling, has been reported to be lacking in high-risk chronic lymphocytic leukemia. However, its correlation with biological variables and its prognostic significance remain unknown. We investigated 311 consecutive patients, prospectively enrolled since 2007. Methods for studying patients were standardized and included clinical assessment, immunophenotype, fluorescence in situ hybridization, and status of immunoglobulin heavy chain variable region genes. Overall, 22.1% of patients had Binet stage B or C disease, 38.5% had unmutated immunoglobulin genes, 15.1% had high-risk cytogenetic abnormalities, 23.4% were CD38+, 37.8% CD49d+, and 59.8% LAIR1+. Expression of LAIR1 was inversely related to that of CD38 (P=0.0005), but was not associated with CD49d expression (P=0.96). A significantly lower expression of LAIR1 was observed in patients with Binet stage B or C disease (P=0.023), and in the presence of high-risk cytogenetic abnormalities (P=0.048) or unmutated immunoglobulin heavy chain variable region genes (P+ was significantly associated with longer time to first treatment (P=0.0002). This favorable effect of LAIR1+ was confirmed by multivariate analysis (hazard ratio=2.1, P=0.03 for LAIR1). Our results indicate that LAIR1 expression is a reliable and inexpensive marker capable of independently predicting time to first treatment in newly diagnosed unselected patients with chronic lymphocytic leukemia.
https://doi.org/10.3324/haematol.2013.096362
10.3324/haematol.2013.096362
Dive into the research topics of 'Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia'. Together they form a unique fingerprint.
B-Cell Chronic Lymphocytic Leukemia Medicine & Life Sciences 100%
Flow Cytometry Medicine & Life Sciences 71%
Immunoglobulin Heavy Chains Medicine & Life Sciences 40%
leukocyte-associated immunoglobulin-like receptor 1 Medicine & Life Sciences 30%
Chromosome Aberrations Medicine & Life Sciences 30%
Immunoglobulin Genes Medicine & Life Sciences 19%
Fluorescence In Situ Hybridization Medicine & Life Sciences 15%
Perbellini, O., Falisi, E., Giaretta, I., Boscaro, E., Novella, E., Facco, M., Fortuna, S., Finotto, S., Amati, E., Maniscalco, F., Montaldi, A., Alghisi, A., Aprili, F., Bonaldi, L., Paolini, R., Scupoli, M. T., Trentin, L., Ambrosetti, A., Semenzato, G., ... Visco, C. (2014). Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia. Haematologica, 99(5), 881-887. https://doi.org/10.3324/haematol.2013.096362
Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia. / Perbellini, Omar; Falisi, Erika; Giaretta, Ilaria et al.
In: Haematologica, Vol. 99, No. 5, 01.05.2014, p. 881-887.
Perbellini, O, Falisi, E, Giaretta, I, Boscaro, E, Novella, E, Facco, M, Fortuna, S, Finotto, S, Amati, E, Maniscalco, F, Montaldi, A, Alghisi, A, Aprili, F, Bonaldi, L, Paolini, R, Scupoli, MT, Trentin, L, Ambrosetti, A, Semenzato, G, Pizzolo, G, Rodeghiero, F & Visco, C 2014, 'Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia', Haematologica, vol. 99, no. 5, pp. 881-887. https://doi.org/10.3324/haematol.2013.096362
Perbellini O, Falisi E, Giaretta I, Boscaro E, Novella E, Facco M et al. Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia. Haematologica. 2014 May 1;99(5):881-887. doi: 10.3324/haematol.2013.096362
Perbellini, Omar ; Falisi, Erika ; Giaretta, Ilaria et al. / Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia. In: Haematologica. 2014 ; Vol. 99, No. 5. pp. 881-887.
@article{b13f4e3d611743509e30f06b235c57e4,
title = "Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia",
abstract = "Most patients affected by chronic lymphocytic leukemia are diagnosed by flow cytometry. Several immunophenotypic markers have been identified as significant and independent prognostic variables, especially from retrospective cohorts. However, while attractive because their detection is inexpensive and feasible in most laboratories, only few have been validated by independent series. The expression of leukocyte-associated immunoglobulin-like receptor-1 (also known as LAIR1, LAIR-1 or CD305), an inhibitor of B-cell receptor-mediated signaling, has been reported to be lacking in high-risk chronic lymphocytic leukemia. However, its correlation with biological variables and its prognostic significance remain unknown. We investigated 311 consecutive patients, prospectively enrolled since 2007. Methods for studying patients were standardized and included clinical assessment, immunophenotype, fluorescence in situ hybridization, and status of immunoglobulin heavy chain variable region genes. Overall, 22.1% of patients had Binet stage B or C disease, 38.5% had unmutated immunoglobulin genes, 15.1% had high-risk cytogenetic abnormalities, 23.4% were CD38+, 37.8% CD49d+, and 59.8% LAIR1+. Expression of LAIR1 was inversely related to that of CD38 (P=0.0005), but was not associated with CD49d expression (P=0.96). A significantly lower expression of LAIR1 was observed in patients with Binet stage B or C disease (P=0.023), and in the presence of high-risk cytogenetic abnormalities (P=0.048) or unmutated immunoglobulin heavy chain variable region genes (P+ was significantly associated with longer time to first treatment (P=0.0002). This favorable effect of LAIR1+ was confirmed by multivariate analysis (hazard ratio=2.1, P=0.03 for LAIR1). Our results indicate that LAIR1 expression is a reliable and inexpensive marker capable of independently predicting time to first treatment in newly diagnosed unselected patients with chronic lymphocytic leukemia.",
author = "Omar Perbellini and Erika Falisi and Ilaria Giaretta and Elisa Boscaro and Elisabetta Novella and Monica Facco and Stefania Fortuna and Silvia Finotto and Eliana Amati and Francesco Maniscalco and Anna Montaldi and Alberta Alghisi and Fiorenza Aprili and Laura Bonaldi and Rossella Paolini and Scupoli, {Maria Teresa} and Livio Trentin and Achille Ambrosetti and Gianpietro Semenzato and Giovanni Pizzolo and Francesco Rodeghiero and Carlo Visco",
doi = "10.3324/haematol.2013.096362",
journal = "Haematologica",
publisher = "NLM (Medline)",
T1 - Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia
AU - Perbellini, Omar
AU - Falisi, Erika
AU - Giaretta, Ilaria
AU - Boscaro, Elisa
AU - Novella, Elisabetta
AU - Facco, Monica
AU - Fortuna, Stefania
AU - Finotto, Silvia
AU - Amati, Eliana
AU - Maniscalco, Francesco
AU - Montaldi, Anna
AU - Alghisi, Alberta
AU - Aprili, Fiorenza
AU - Bonaldi, Laura
AU - Paolini, Rossella
AU - Scupoli, Maria Teresa
AU - Trentin, Livio
AU - Ambrosetti, Achille
AU - Semenzato, Gianpietro
AU - Pizzolo, Giovanni
AU - Rodeghiero, Francesco
AU - Visco, Carlo
N2 - Most patients affected by chronic lymphocytic leukemia are diagnosed by flow cytometry. Several immunophenotypic markers have been identified as significant and independent prognostic variables, especially from retrospective cohorts. However, while attractive because their detection is inexpensive and feasible in most laboratories, only few have been validated by independent series. The expression of leukocyte-associated immunoglobulin-like receptor-1 (also known as LAIR1, LAIR-1 or CD305), an inhibitor of B-cell receptor-mediated signaling, has been reported to be lacking in high-risk chronic lymphocytic leukemia. However, its correlation with biological variables and its prognostic significance remain unknown. We investigated 311 consecutive patients, prospectively enrolled since 2007. Methods for studying patients were standardized and included clinical assessment, immunophenotype, fluorescence in situ hybridization, and status of immunoglobulin heavy chain variable region genes. Overall, 22.1% of patients had Binet stage B or C disease, 38.5% had unmutated immunoglobulin genes, 15.1% had high-risk cytogenetic abnormalities, 23.4% were CD38+, 37.8% CD49d+, and 59.8% LAIR1+. Expression of LAIR1 was inversely related to that of CD38 (P=0.0005), but was not associated with CD49d expression (P=0.96). A significantly lower expression of LAIR1 was observed in patients with Binet stage B or C disease (P=0.023), and in the presence of high-risk cytogenetic abnormalities (P=0.048) or unmutated immunoglobulin heavy chain variable region genes (P+ was significantly associated with longer time to first treatment (P=0.0002). This favorable effect of LAIR1+ was confirmed by multivariate analysis (hazard ratio=2.1, P=0.03 for LAIR1). Our results indicate that LAIR1 expression is a reliable and inexpensive marker capable of independently predicting time to first treatment in newly diagnosed unselected patients with chronic lymphocytic leukemia.
AB - Most patients affected by chronic lymphocytic leukemia are diagnosed by flow cytometry. Several immunophenotypic markers have been identified as significant and independent prognostic variables, especially from retrospective cohorts. However, while attractive because their detection is inexpensive and feasible in most laboratories, only few have been validated by independent series. The expression of leukocyte-associated immunoglobulin-like receptor-1 (also known as LAIR1, LAIR-1 or CD305), an inhibitor of B-cell receptor-mediated signaling, has been reported to be lacking in high-risk chronic lymphocytic leukemia. However, its correlation with biological variables and its prognostic significance remain unknown. We investigated 311 consecutive patients, prospectively enrolled since 2007. Methods for studying patients were standardized and included clinical assessment, immunophenotype, fluorescence in situ hybridization, and status of immunoglobulin heavy chain variable region genes. Overall, 22.1% of patients had Binet stage B or C disease, 38.5% had unmutated immunoglobulin genes, 15.1% had high-risk cytogenetic abnormalities, 23.4% were CD38+, 37.8% CD49d+, and 59.8% LAIR1+. Expression of LAIR1 was inversely related to that of CD38 (P=0.0005), but was not associated with CD49d expression (P=0.96). A significantly lower expression of LAIR1 was observed in patients with Binet stage B or C disease (P=0.023), and in the presence of high-risk cytogenetic abnormalities (P=0.048) or unmutated immunoglobulin heavy chain variable region genes (P+ was significantly associated with longer time to first treatment (P=0.0002). This favorable effect of LAIR1+ was confirmed by multivariate analysis (hazard ratio=2.1, P=0.03 for LAIR1). Our results indicate that LAIR1 expression is a reliable and inexpensive marker capable of independently predicting time to first treatment in newly diagnosed unselected patients with chronic lymphocytic leukemia.
U2 - 10.3324/haematol.2013.096362
DO - 10.3324/haematol.2013.096362
JO - Haematologica
JF - Haematologica